Lite Strategy (LITS) Operating Margin (2016 - 2023)
Lite Strategy (LITS) posted quarterly Operating Margin of 84.66% for Q3 2023, up 29336.0% year-over-year from N/an in Q3 2022, and up 111.13% quarter-over-quarter from 760.47% in Q2 2023.
Lite Strategy (LITS) Operating Margin (2016 - 2023) Analysis & Trends
Lite Strategy's Operating Margin history runs 8 years deep, the most recent figure standing at 84.66% for Q3 2023.
- In Q3 2023, Operating Margin rose 29336.0% year-over-year to 84.66%; the TTM figure through Jun 2024 stood at 22.27% (up 9758.0% YoY), while the FY2024 annual figure was 22.27%, up 9758.0% from the prior year.
- Operating Margin for Q3 2023 stood at 84.66%, up from 760.47% in the prior quarter.
- The five-year high for Operating Margin was 84.66% in Q3 2023, with the low at 1201.29% in Q4 2019.
- The 5-year median for Operating Margin is 208.69% (2022), against an average of 417.55%.
- The sharpest annual moves came in 2019 and 2020: Operating Margin slumped 62306 bps in 2019, then surged 108557 bps in 2020.
- Lite Strategy's Operating Margin stood at 1201.29% in 2019, then jumped by 90 bps to 125.23% in 2020, then declined by 19 bps to 148.96% in 2021, then soared by 118 bps to 27.27% in 2022, then soared by 210 bps to 84.66% in 2023.
- Business Quant data shows LITS's Operating Margin at 84.66% in Q3 2023, 760.47% in Q2 2023, and 278.1% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Lite Strategy | 36.25 Mn | 28.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 84.66% |
| Jun 30, 2023 | -760.47% |
| Mar 31, 2023 | -278.10% |
| Dec 31, 2022 | 27.27% |
| Sep 30, 2022 | -208.69% |
| Jun 30, 2022 | -141.90% |
| Mar 31, 2022 | -222.38% |
| Dec 31, 2021 | -148.96% |
| Sep 30, 2021 | -259.19% |
| Jun 30, 2021 | -207.59% |
| Mar 31, 2021 | -202.18% |
| Dec 31, 2020 | -125.23% |
| Sep 30, 2020 | -192.56% |
| Jun 30, 2020 | 45.00% |
| Mar 31, 2020 | -1,000.24% |
| Dec 31, 2019 | -1,201.29% |
| Sep 30, 2019 | -1,091.01% |
| Jun 30, 2019 | -1,040.57% |
| Mar 31, 2019 | -1,010.09% |
| Dec 31, 2018 | -578.23% |